# Small molecule enhancers of tumor immunity targeting the LPA5 GPCR

> **NIH NIH R01** · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 2022 · $861,845

## Abstract

Lysophosphatidic acid (LPA) GPCR subtype 5 (LPAR5) is abundantly expressed by human and murine CD8
cytotoxic T lymphocytes (CTLs) and functions as an inhibitory receptor that represses T cell receptor (TCR)
signaling leading to inhibition of tumor immunity. Specifically, stimulation of LPAR5 by physiological levels of
LPA significantly impedes antigen specific TCR-induced Ca2+ mobilization, T cell activation, proliferation and
cytolytic tumor cell killing functions, resulting in an impaired anti-tumor immune response. Indeed, CD8+ T cells
lacking LPAR5 expression are more effective at reducing the growth rate of EG7 lymphoma and B16 melanoma
tumors in mice compared to wild type (WT) CD8+ T cells. Moreover, Lpar5 -/- mice have 85% reduction in the
incidence of B16 melanoma-derived lung metastasis compared to WT littermates, with a robust CD8+ CTL
infiltration observed in the Lpar5 -/- mice that developed few lung metastasis. These data highlight a unique role
for LPAR5 as an immune checkpoint molecule regulating immune surveillance and cytotoxic effector function.
The objective of this proposal is to identify small molecule inhibitors of LPAR5 as clinically applicable
immunomodulators for cancer treatment. A virtual screening (VS) of 2 million compounds using validated
LPAR models identified more than 300 hits of which 90 were selective for LPAR5 antagonist compounds with
diverse scaffolds. In addition, a high throughput screening (HTS) campaign of 200K compounds and secondary
analyses of 19 validated hits have already resulted in the identification of two distinct molecular scaffolds. The
most promising hit, SRI-42730, demonstrated LPAR5 antagonism in five independent assays: β-arrestin
recruitment, Ca2+ mobilization, TGFα-shedding, IL-2 production implemented in HTS platform and in vivo
efficacy in the B16 murine melanoma metastasis model. The novel hits and analogs we have already identified
will be used as tool compounds in the following proposed studies: 1) Perform hit-to-lead medicinal chemistry
optimization of LPAR5 antagonists. Computational approaches will include scaffold hopping on HTS hits, and
the generation of a pharmacophore model to aid synthetic optimization of potency and selectivity of newly
designed analogs; 2) Determine the specificity of novel antagonists at LPA GPCR subtypes and autotaxin
lysophospholipase enzyme; 3) Rank specific antagonist hits by potency in boosting antigen-specific TCR
activation and IL-2 production in the presence of LPA; 4). 8 key compounds will then be evaluated in cellular
assays from which 3 compounds will undergo PK analysis prior to in vivo tox studies and animal efficacy
studies. 5) Determine efficacy of nominated three potential lead compounds in boosting tumor immunity
using murine and allogeneic human in vitro tumor killing assays and in vivo murine metastasis seeding and
progression models. The impact of this research will be the identification and nomination of a single lead
compound and a p...

## Key facts

- **NIH application ID:** 10535248
- **Project number:** 1R01CA266207-01A1
- **Recipient organization:** UNIVERSITY OF TENNESSEE HEALTH SCI CTR
- **Principal Investigator:** CORINNE ELIZABETH AUGELLI-SZAFRAN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $861,845
- **Award type:** 1
- **Project period:** 2022-08-01 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10535248

## Citation

> US National Institutes of Health, RePORTER application 10535248, Small molecule enhancers of tumor immunity targeting the LPA5 GPCR (1R01CA266207-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10535248. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*